Squarepoint Ops LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 60,936 shares of the company’s stock, valued at approximately $385,000.
A number of other institutional investors have also recently bought and sold shares of the business. Virtu Financial LLC bought a new position in shares of ImmunityBio in the 4th quarter valued at $304,000. Brookstone Capital Management bought a new position in ImmunityBio in the 1st quarter worth approximately $100,000. Courier Capital LLC lifted its holdings in shares of ImmunityBio by 33.3% in the first quarter. Courier Capital LLC now owns 20,000 shares of the company’s stock worth $107,000 after buying an additional 5,000 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of ImmunityBio by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 128,321 shares of the company’s stock valued at $689,000 after acquiring an additional 51,086 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in ImmunityBio by 41.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,411 shares of the company’s stock valued at $319,000 after purchasing an additional 17,549 shares in the last quarter. Institutional investors own 8.58% of the company’s stock.
ImmunityBio Stock Performance
NASDAQ IBRX opened at $3.23 on Friday. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -2.96 and a beta of 1.02. The stock has a 50-day moving average of $3.81 and a 200 day moving average of $5.48. ImmunityBio, Inc. has a one year low of $1.25 and a one year high of $10.53.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler reduced their target price on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a research note on Monday, August 19th.
View Our Latest Analysis on ImmunityBio
ImmunityBio Profile
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Further Reading
- Five stocks we like better than ImmunityBio
- What Are Dividend Challengers?
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What Are the FAANG Stocks and Are They Good Investments?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- What Are Growth Stocks and Investing in Them
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX – Free Report).
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.